Metabolite Identification Studies
The FDA guidance for Safety Testing of Drug Metabolites recommends that the structure of any metabolite which may represent more than 10 % of the exposure in humans should be formally elucidated. The earlier a disproportionate metabolite is recognized and characterised in the drug development process, the lower the risk of downstream delays with better planning of clinical studies.
The expertise and experience, in conjunction with state-of-the-art technology, are available within Arcinova to advise on the optimal approaches for completion of metabolite isolation and identification. Where possible, isolation can be circumvented by hyphenated technologies. The in-house mass spectrometry – Nuclear Magnetic Resonance platform not only enables identification of metabolites, but it permits quantification within a biological matrix.
SMi Highly Potent Active Pharmaceutical IngredientsThe SMi Highly Potent Active Pharmaceutical Ingredients Conference will be attended by Mark Anstiss, Scale-up Chemist.
SMi Highly Potent Active Pharmaceutical IngredientsDates: 21st - 22nd MayLocation: Birmingham, UK
66th Annual ASMS ConferenceThe 66th ASMS Conference on Mass Spectrometry and Allied Topics Conference will be attended by Michael Blackburn, Method Development Scientist (Physiochemical). Michael will also be presenting during the conference, at the Proteins & Peptides Waters Users Meeting, with a presentation entitled; A Powerful Hybrid IA-LC-MS/MS Method Quantification of Insulin Analogues and
66th Annual ASMS ConferenceDates: 3rd - 7th JuneLocation: San Diego, US
2018 BIO International ConventionThe 2018 BIO International Convention will be attended by Mark Chadwick, Head of Business Development.
2018 BIO International ConventionDates: 4th - 7th JuneLocation: Boston, USA